Vivani Medical, Inc.
Close on Oct 19, 2026
- Market cap
- $97.54M
- P/E (TTM)
- –
- Dividend yield
- –
About Vivani Medical
Electromedical & Electrotherapeutic Apparatus, SIC 3845
Vivani Medical, Inc. is a clinical-stage biopharmaceutical company that develops miniature, ultra long-acting subdermal drug implants. Using its proprietary NanoPortal technology, the company designs implants intended to provide reversible, near constant-rate delivery of therapeutic agents to treat chronic conditions such as obesity and type 2 diabetes. Its lead product candidate is NPM-139, a six-month semaglutide implant for chronic weight management. The company is also developing NPM-133, a semaglutide implant for type 2 diabetes, NPM-115, an exenatide implant for chronic weight management, and OKV-119, an implant for chronic weight management in companion animals developed in partnership with Okava Pharmaceuticals.
Vivani conducts clinical trials in Australia, including its LIBERATE-1 study at two Australian study centers. In addition, the company maintains a subsidiary in Australia and holds pioneering neurostimulation technology assets within its wholly owned subsidiary, Cortigent, Inc. The company's principal executive offices and headquarters are located in Alameda, California.
Summary of the business section of Vivani Medical's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Vivani Medical, Inc.
- Headquarters
- Alameda, CA
- Address
- 1350 S. Loop Road 94502
- Phone
- (415) 506-8462
- Website
- vivani.com
- Employees
- 36, Dec 31, 2025
- Industry
- Electromedical & Electrotherapeutic Apparatus
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- BPM LLP, Walnut Creek, California
Stock & identifiers
- Ticker
- VANI
- Exchange
- Nasdaq
- IPO date
- Nov 19, 2014
- Shares outstanding
- 90M, Aug 13, 2026
- Public float
- $45.90M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- Stock splits
- 1-for-3 reverse, Aug 19, 2022; 1-for-8 reverse, Jan 6, 2020; 1-for-8 reverse, Jan 6, 2020
- SEC CIK
- 1266806
- CUSIP
- 92854B109
- ISIN
- US92854B1098
- LEI
- 5299004VTNX49EZIFL05
- EIN
- 02-0692322
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Adam Mendelsohn | Chief Executive Officer, Director | 3,695,573 |
| Anthony Baldor | Chief Financial Officer | – |
| Truc Le | Chief Operations Officer | 0 |
| Lisa Ellen Porter | Chief Medical Officer | 0 |
| Donald Dwyer | Chief Business Officer | 55,000 |
| Brigid Makes | Chief Financial Officer | 15,000 |
| Daniel Bradbury | Director | 0 |
| Gregg Williams | Director | 41,711,936 |
| August J. Moretti | Director | – |
| Aaron Mendelsohn | Director | 1,086,487 |
| Alexandra L. Popoff | Director | 2,166 |
| Wilford Dean Baker | Director | 197,482 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 Adam Mendelsohn | $877.58K | $856.95K | $750.93K | $145 | – |
| FY2024 | $1.08M | $915.16K | $770.40K | $137 | – |
| FY2024 Adam Mendelsohn | $1.08M | $915.16K | $770.40K | $137 | – |
| FY2024 Peo1 | $0 | $0 | $770.40K | $137 | – |
| FY2024 Peo2 | $1.08M | $915.16K | $770.40K | $137 | – |
| FY2023 Adam Mendelsohn | $1.04M | $954.82K | $693.52K | $120 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“As of December 31, 2025 , we had 36 employees in our Biopharm Division and 6 employees in Cortigent.”
Corporate history
Events identified from SEC filings